Development of population pharmacokinetics model of icotinib with non-linear absorption characters in healthy Chinese volunteers to assess the CYP2C19 polymorphism and food-intake effect

详细信息    查看全文

• 作者：Pei Hu ; Jia Chen ; Dongyang Liu ; Xin Zheng…
• 关键词：Icotinib ; Population pharmacokinetics ; Non ; linear absorption ; CYP2C19 polymorphism ; Food intake
• 刊名：European Journal of Clinical Pharmacology
• 出版年：2015
• 出版时间：July 2015
• 年：2015
• 卷：71
• 期：7
• 页码：843-850
• 全文大小：708 KB
• 参考文献：1.Camidge DR (2013) Icotinib: kick-starting the Chinese anticancer drug industry. Lancet Oncol 14(10):913-14. doi:10.-016/?S1470-2045(13)70385-1 PubMed View Article
  2.Tan F, Shen X, Wang D, Xie G, Zhang X, Ding L, Hu Y, He W, Wang Y (2012) Icotinib (BPI-2009H), a novel EGFR tyrosine kinase inhibitor, displays potent efficacy in preclinical studies. Lung Cancer 76(2):177-82. doi:10.-016/?j.?lungcan.-011.-0.-23 PubMed View Article
  3.Gao Z, Chen W, Zhang X, Cai P, Fang X, Xu Q, Sun Y, Gu Y (2013) Icotinib, a potent and specific EGFR tyrosine kinase inhibitor, inhibits growth of squamous cell carcinoma cell line A431 through negatively regulating AKT signaling. Biomed Pharmacother 67(5):351-56. doi:10.-016/?j.?biopha.-013.-3.-12 PubMed View Article
  4.Mu X, Zhang Y, Qu X, Hou K, Kang J, Hu X, Liu Y (2013) Ubiquitin ligase Cbl-b is involved in icotinib (BPI-2009H)-induced apoptosis and G1 phase arrest of EGFR mutation-positive non-small-cell lung cancer. Biomed Res Int 2013:726375. doi:10.-155/-013/-26375 PubMed Central PubMed View Article
  5.Shi Y, Zhang L, Liu X, Zhou C, Zhang S, Wang D, Li Q, Qin S, Hu C, Zhang Y, Chen J, Cheng Y, Feng J, Zhang H, Song Y, Wu YL, Xu N, Zhou J, Luo R, Bai C, Jin Y, Liu W, Wei Z, Tan F, Wang Y, Ding L, Dai H, Jiao S, Wang J, Liang L, Zhang W, Sun Y (2013) Icotinib versus gefitinib in previously treated advanced non-small-cell lung cancer (ICOGEN): a randomised, double-blind phase 3 non-inferiority trial. Lancet Oncol 14(10):953-61. doi:10.-016/?S1470-2045(13)70355-3 PubMed View Article
  6.Shao L, Zhang B, He C, Lin B, Song Z, Lou G, Yu X, Zhang Y (2014) Efficacy and safety of icotinib in Chinese patients with advanced non-small cell lung cancer after failure of chemotherapy. Chin Med J (Engl) 127(2):266-71
  7.Wang HP, Zhang L, Wang YX, Tan FL, Xia Y, Ren GJ, Hu P, Jiang J, Wang MZ, Xiao Y (2011) Phase I trial of icotinib, a novel epidermal growth factor receptor tyrosine kinase inhibitor, in Chinese patients with non-small cell lung cancer. Chin Med J (Engl) 124(13):1933
  8.Zhao Q, Shentu J, Xu N, Zhou J, Yang G, Yao Y, Tan F, Liu D, Wang Y (2011) Phase I study of icotinib hydrochloride (BPI-2009H), an oral EGFR tyrosine kinase inhibitor, in patients with advanced NSCLC and other solid tumors. Lung Cancer 73(2):195-02. doi:10.-016/?j.?lungcan.-010.-1.-07 PubMed View Article
  9.Ruan CJ, Liu DY, Jiang J, Hu P (2012) Effect of the CYP2C19 genotype on the pharmacokinetics of icotinib in healthy male volunteers. Eur J Clin Pharmacol 68(12):1677-680. doi:10.-007/?s00228-012-1288-4 PubMed View Article
  10.Jackson KA, Rosenbaum SE (1998) The application of population pharmacokinetics to the drug development process. Drug Dev Ind Pharm 24(12):1155-162. doi:10.-109/-363904980910857- PubMed View Article
  11.Pene Dumitrescu T, Anic-Milic T, Oreskovic K, Padovan J, Brouwer KL, Zuo P, Schmith VD (2013) Development of a population pharmacokinetic model to describe azithromycin whole-blood and plasma concentrations over time in healthy subjects. Antimicrob Agents Chemother 57(7):3194-201. doi:10.-128/?AAC.-2430-12 PubMed Central PubMed View Article
  12.Liu D, Jiang J, Hu P, Tan F, Wang Y (2009) Quantitative determination of icotinib in human plasma and urine using liquid chromatography coupled to tandem mass spectrometry. J Chromatogr B Analyt Technol Biomed Life Sci 877(30):3781-786. doi:10.-016/?j.?jchromb.-009.-8.-55 PubMed View Article
  13.Yafune A, Ishiguro M (1999) Bootstrap approach for constructing confidence intervals for population pharmacokinetic parameters. II: a bootstrap modification of standard two-stage (STS) method for phase I trial. Stat Med 18(5):601-12. doi:10.-002/-SICI)1097-0258(19990315)18:-<601:-?AID-SIM48>3.-.?CO;2-L PubMed View Article
  14.Yafune A, Ishiguro M (1999) Bootstrap approach for constructing confidence intervals for population pharmacokinetic parameters. I: a use of bootstrap standard error. Stat Med 18(5):581-99. doi:10.-002/-SICI)1097-0258(19990315)18:-<581:-?AID-SIM47>3.-.?CO;2-1 PubMed View Article
  15.Wang DD, Zhang S (2012) Standardized visual predictive check versus visual predictive check for model evaluation. J Clin Pharmacol 52(1):39-4. doi:10.-177/-091270010390040-/span> PubMed View Article
  16.Savic RM, Karlsson MO (2009) Importance of shrinkage in empirical Bayes estimates for diagnostics: problems and solutions. AAPS J 11(3):558-69. doi:10.-208/?s12248-009-9133-0 PubMed Central PubMed View Article
  17.Liu D, Jiang J, Zhang L, Tan F, Wang Y, Zhang D, Hu P (2014) Clinical pharmacokinetics of Icotinib, an anti-cancer drug: evaluation of dose proportionality, food effect, and tolerability in healthy subjects. Cancer Chemother Pharmacol. doi:10.-007/?s00280-014-2398-8
  18.Lentz KA (2008) Current methods for predicting human food effect. AAPS J 10(2):282-88. doi:10.-208/?s12248-008-9025-8 PubMed Central PubMed View Article
  19
• 作者单位：Pei Hu (1)
  Jia Chen (1)
  Dongyang Liu (1)
  Xin Zheng (1)
  Qian Zhao (1)
  Ji Jiang (1)
  
  1. Clinical Pharmacology Research Center, Peking Union Medical College Hospital and Chinese Academy of Medical Sciences, Beijing, China
  
• 刊物类别：Biomedical and Life Sciences
• 刊物主题：Biomedicine
  Pharmacology and Toxicology
  
• 出版者：Springer Berlin / Heidelberg
• ISSN：1432-1041

文摘

Purpose Icotinib is a potent and selective inhibitor of epidermal growth factor receptors (EGFR) approved to treat non-small cell lung cancer (NSCLC). However, its high variability may impede its application. The objectives of this analysis were to assess plasma pharmacokinetics and identify covariates that may explain variability in icotinib absorption and/or disposition following single dose of icotinib in healthy volunteers. Methods Data from two clinical studies (n--2) were analyzed. One study was designed as three-period and Latin-squared (six sequence) trial to evaluate dose proportionality, and the other one was designed as two-way crossover trial to evaluate food effect on pharmacokinetics (PK) characters. Icotinib concentrations in plasma were analyzed using non-linear mixed-effects model (NONMEM) method. The model was used to assess influence of food, demographic characteristics, measurements of blood biochemistry, and CYP2C19 genotype on PK characters of icotinib in humans. The final model was diagnosed by goodness-of-fit plots and evaluated by visual predictive check (VPC) and bootstrap methods. Results A two-compartment model with saturated absorption character was developed to capture icotinib pharmacokinetics. Typical value of clearance, distribution clearance, central volume of distribution, maximum absorption rate were 29.5?L/h, 24.9?L/h, 18.5?L, 122.2?L and 204,245?μg/h, respectively. When icotinib was administrated with food, bioavailability was estimated to be increased by 48?%. Inter-occasion variability was identified to affect on maximum absorption rate constant in food-effect study. CL was identified to be significantly influenced by age, albumin concentration (ALB), and CYP2C19 genotype. No obvious bias was found by VPC and bootstrap methods. Conclusions The developed model can capture icotinib pharmacokinetics well in healthy volunteers. Food intake can increase icotinib exposure. Three covariates, age, albumin concentration, and CYP2C19 genotype, were identified to significantly affect icotinib PK profiles in healthy subjects.